Genexine is a clinical stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next generation novel long-acting biologics. Our goal is to bring to patients medicines that will transform their lives.

Board of Directors

Young Chul Sung, Ph.D.
Founder & CEO, Genexine
and Chairman of the Board of Directors
Hyi-Jeong Ji, Ph.D.
President, CTO
You Suk Suh, Ph.D.
Senior Vice President, DNA Research Institute
Young-Jin Kim
Chairman & CEO, Handok
Tae Yong Lee
CEO, Intervest
HyukJong Lee, MBA
CEO/President, Binex Co. Ltd.
Eui-Cheol Shin, M.D., Ph.D.
Professor, KAIST GSMSE


Young Chul Sung
Hyi-Jeong Ji
Jung Won Woo
Executive Vice President,
Jong Sup Park
M.D., Ph.D.
Gynecologic Oncologist


Kyu Don Kim
Business Development
Kwang Ho Kim
Yong Min Won
Han lim Moon
M.D., Ph.D.

   Previous Next   
  • Young Chul Sung, Ph.D.
    Chairman, CEO
    Young Chul Sung is the founder and former CEO of Genexine. He currently serves as Chief Technology Officer of Genexine. He is also a professor at POSTECH Department of Life Sciences and founder of POSTECH- Catholic Bio Medical Institute. Dr. Sung is an expert immunologist and has published over one hundred scientific articles. He has served on editorial boards of many biological organizations and has earned numerous awards including the most recently the Scientists of the Year 2014 from Korea Science Journalist Association. Dr. Sung received his B.S. from Yonsei University, Ph.D degree from University of Minnesota and postdoctoral training at Harvard University.
  • Hyi-Jeong Ji, Ph.D.
    President, CTO
    Hyi-Jeong Ji is Executive Vice President and Head of Bio Research Institute and joined Genexine in January 2018. Prior to joining Genexine, Dr. Ji held Senior Vice President position of Corporate Development at GreenGross Corp. Prior to that, she served as Vice President of Product Development Division in LG Life Sciences Ltd leading hGH Development project. Dr. Ji received B.S and M.S in Biochemistry from Yonsei University, Ph.D. in Biochemistry from Purdue University, and MBA degree from LG MBA.
  • Jung Won Woo, Ph.D.
    Executive Vice President, CDO/COO
    Jung won Woo is in charge of Clinical Planning and joined Genexine in 2013. Previously, Dr. Woo was Senior Researcher at Samsung Bio Research Institute and later at Convergent Research Consortium for Immunologic Disease in Seoul St Mary’s Hospital. Dr. Woo received her B.S. and M.S. in Pharmacy from Seoul National University and Ph.D. in Microbiology from Cornell University. She did her postdoctoral fellowship at Harvard Medical School.
  • Jong Sup Park, M.D., Ph.D.
    Gynecologic Oncologist
    Jong Sup Park joined Genexine as Executive Vice President and Chief Medical Officer since March 2019 after retirement in Catholic Medical Center. Dr. Park had served as a Director in Gynecological Cancer Center of Seoul St. Mary’s Hospital, Catholic University of Korea and remains as Professor Emeritus. Also, he was former research professor at Johns Hopkins medical school, department of microbiology. He had dedicated himself as a representative Gynecologic Oncologist in Korea as well as a well-known Biomedical Researcher on HPV and Cervical Cancer for 30 years. In addition, he established AOGIN (Asia-Oceania Research Organization on Genital Infection and Neoplasia) to educate clinicians and health workers who were living in Asia-Pacific region.
  • Kyu Don Kim, Ph.D. MBA
    Advisor, Business Development
    Kyu Don Kim joined Genexine in December 2015 as Excutive Vice President and he is in charge of Business. Prior to joining Genexine, Dr Kim was CEO at CKD and Bio Business Team of New Business Division in Samsung Electronics and held the position of Vice President . Prior to that, he served as Head of Product Development Division in LG Life Sciences Ltd. Dr Kim received his B.S in Biochemistry from Yonsei University, MBA degree from Sogang University and Ph.D. in Chemistry from University of Northern Illinois and postdoctoral training at University of Florida, Gainesville.
  • Kwang Ho Kim
    Advisor, HR
    KwangHo Kim joined Genexine as Chief Operating Officer in 2018 from Johnson and Johnson, where he led its North Asia Consumer business as Area Managing Director. Prior to JnJ, Mr. Kim worked at Mars Inc. for sixteen years in various executive roles including Head of North Asia and General Manager Korea. Mr. Kim started his career at Samsung where he worked in a number of engineering projects for ten years. Mr. Kim received his B.A. in Mechanical Engineering from Pusan National University.
  • Yong Min Won, MBA
    Advisor, Finance
    Yong Min Won joined Genexine in April 2017 as Chief Financial Officer, and he is in charge of Finance and IR/PR. Prior to joining Genexine, Mr. Won served as Executive Director at Handok Inc. for five years. Prior to that, he was Head of International Business in Hana Daetoo Securities and have more than 17 years’ experience in financial industry. Mr. Won received his B.A in Business Administration from Korea University and MBA degree from Cornell University.
  • Hanlim Moon, M.D., Ph.D.
    Advisor, Clinical
    Dr Hanlim Moon is a highly regarded industry oncologist with more than thirty years ’experience in oncology clinical research internationally. Throughout her career, she has held several senior corporate leadership positions, led innovative pre-clinical & clinical research divisions and diverse medical teams, been head of a business development unit, and worked as an independent consultant on a substantial array of high-value oncology projects. Her experience includes portfolio development, early clinical programs, P3 registration activities and late-phase studies to support marketed therapeutics. Dr Moon is widely regarded as an international leading industry opinion leader. She is particularly adept at dealing with R & D strategy and the effective conduct of related clinical research globally. Her broad network of academic and industry contacts reflects her outstanding skills as a collaborator and mentor. She also offers highly specialized expertise in clinical approaches to the development of novel therapies for both solid and hematological cancers.


Sung Ki Baik, Ph.D.
Director, Korea-Asean Friendship Association


Introduction of Genexine CI

Logo Framework

The Genexine logo consists of the brand name.

Minimum Size

The Genexine logo must appear in the specified proportions. The Genexine logo should not be reproduced smaller than the minimum recommended size of 0.5” H x 1.5” W for printing materials.

Corporate Colors

Consistent use of color across all media is essential to the integrity of the Genexine identity. Below are the approved color variations for print (CMYK) and web (RGB) formats. Note that no other color specifications should be utilized. The Genexine logo may be used on any medium with a white background.

Full Color | White Background
  • Print: CMYK

    C=100 M=25 Y=0 K=50

    Web/Screen (includes powerpoint): RGB

    R=0 G=85 B=129

  • Print: CMYK

    C=0 M=100 Y=79 K=20

    Web/Screen (includes powerpoint): RGB

    R=196 G=18 B=48

Acceptable Logo

The following examples demonstrate a broad range of background applications.

  • Grayscale | White Background
  • Black | White Background
  • White | Black Background

Incorrect Use

The functional and aesthetic aspect of the logo has been established. Altering the Genexine colors or proportions fractionalize the brand identity and reduce brand recognition.

  • Logo too small
  • Do not use the logo
    on a dark background
  • Do not intrude on
    the visual space of the logo
  • Insufficient background contrast